posted
Botaniex, Inc. To Develop All-Natural Formula for Erectile Dysfunction; Botaniex is poised to capture a share of the multi-billion dollar sexual dysfunction market
Wednesday, June 01, 2005 09:01 ET
Botaniex, Inc. (Pink Sheets: BTXI), announced today that it has initiated the development of an all-natural formula for Erectile Dysfunction (ED). Botaniex has been approached by several multi-national dietary supplement companies that have expressed a strong interest in Botaniex's proposed innovative and all-natural formula for ED. A majority of herbal supplements currently on the market for ED fail to effectively deliver satisfactory results to the consumers. The medically-proven drugs for the treatment of ED include Viagra and Cialis, which are effective but raise health and safety concerns for consumers. In addition, the cost of these drugs is high compared to natural substitutes and can only be purchased with a prescription. Botaniex's goal is to develop a formula that is 100% natural, safe, affordable and as effective as the synthetic drugs for Erectile Dysfunction.
This innovative formula combines herbal and certain animal-based extracts, which should deliver superior results as compared to currently available herbal remedies. This formula incorporates a two centuries-old Chinese folk prescription with highly purified herbal extracts based on Traditional Chinese Medicine theory. Botaniex has completed Phase I of the formulation and has conducted informal clinical trials of the formula. The preliminary results from these trials have been very favourable and most of the patients have exhibited a hard and long-lasting erection. In conjunction with several reputable Research Institutes and hospitals in China, Botaniex will perform official clinical trials of this formula once it is finalized. Botaniex expects to complete the development process in approximately three to five months.
This formula will enable Botaniex to capitalize on the large and high-growth global sexual dysfunction market. Male sexual dysfunction includes erectile dysfunction (ED), loss of libido, premature ejaculation and Peyronie's Disease. These disorders affect more than 175 million men worldwide over the age of 50. In the US alone, the sexual dysfunction medication market generated revenues of approximately $1.91 billion in 2002 and is expected to grow at a Cumulative Annual Growth Rate (2002-2009) of approximately 25.16 percent.
CEO Melson Liao stated: "With Botaniex's expertise and alliance with highly-respected Traditional Chinese Medicine scientists, we are confident that we can develop a formula for ED that helps men who suffer from this disorder to regain their confidence and improve the quality of their family life."
About Botaniex Inc.
Botaniex Inc. is an innovative manufacturer of botanical/herbal extracts, serving the worldwide manufacturers of dietary supplements, health foods, functional beverage, pharmaceuticals and cosmetics. The Company's product line is broad, ranging from tea and herbal extracts to essential oils. Botaniex not only provides customized ingredients, but also offers value-added services such as formulation assistance, clinical trial support and private label manufacturing. The Company is in the process of expanding its operations, including its client and asset-base, in Asia and overseas. Botaniex's goal is to become a major player in the multi-billion dollar global herbal products industry.
For more information please contact CEO Melson Liao at melsonliao@botaniex.com or visit the Corporate website at www.botaniex.com.
Forward-Looking Statements
Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company's stock is not currently registered with the Securities and Exchange Commission.
SOURCE: Botaniex, Inc.
Botaniex, Inc. Melson Liao, 86-20-8702-6371 Fax: 86-20-8702-6237 melsonliao@botaniex.com
Copyright Business Wire 2005
Posts: 2691 | Registered: Dec 2003
| IP: Logged |
posted
I have a feeling the PPS is going up, and will stay up for quite some time. Posts: 1872 | From: right here | Registered: Apr 2004
| IP: Logged |
posted
looks like nobody is playing this one except us hehehe.keep holding this one will repay for all the losses we took from cdvj the previous company.
-------------------- gotta know when to hold em and when to .......... Posts: 1525 | Registered: Mar 2005
| IP: Logged |
posted
Has been very quiet since the news but it's upticking on very low volume today. Ask looks very thin.
Posts: 2691 | Registered: Dec 2003
| IP: Logged |
posted
Botaniex, Inc. Announces $1.5 M in Financing for Construction of Plant
Wednesday, June 22, 2005 09:00 ET
HOUSTON, Jun 22, 2005 (BUSINESS WIRE) --Botaniex, Inc. (BTXI: Pink Sheets), announced today that it has signed a memorandum of understanding for $1.5 million in financing. The Company anticipates closing the financing within the next few weeks. This financing will be utilized to fund the construction of Botaniex's plant, including the purchase of manufacturing equipment and R&D devices, on the recently acquired 16.5-acre parcel of land in Zhaoqing High Technology Industry Development Zone, Guangdong Province, China. In addition, the Company will employ the financing to fulfill current contracts or orders from its customers as well as to assist in securing contracts that are presently under negotiation.
Botaniex's future plant will be a state-of-the-art facility combining two types of extraction technologies - traditional solvent extraction and super-critical fluid extraction (SCFE). This unique combination will provide Botaniex with a significant competitive advantage in the $19 billion natural products industry. The plant will have an annual capacity of 200 metric tonnes of powdered extracts and 40 metric tonnes of essential oils; generating sales of approximately $7,000,000 per annum. Upon completion of this plant, Botaniex will emerge as a key player in the botanical/herbal extracts industry and enable the Company to compete for and secure large orders from multi-national dietary supplements companies.
Botaniex CEO Melson Liao stated: "We are very pleased to have lined up this favorable new funding. It will allow us to proceed with the construction of our plant as scheduled and to meet the market demand for our products. This financing will not only fund our organic or internal growth but also put us in a stronger position to pursue our merger and acquisition (M&A) growth strategy. In fact, we are now in M&A negotiations with two China-based companies - one is a pharmaceutical firm and the other is in the herbal extracts industry. Further details will be disclosed to shareholders once a letter of intent is signed with either firm."
About Botaniex Inc.
Botaniex Inc. is an innovative manufacturer of botanical/herbal extracts, serving the worldwide manufacturers of dietary supplements, health foods, functional beverage, pharmaceuticals and cosmetics. The Company's product line is broad, ranging from tea and herbal extracts to essential oils. Botaniex not only provides customized ingredients, but also offers value-added services such as formulation assistance, clinical trial support and private label manufacturing. The Company is in the process of expanding its operations, including its client and asset-base, in Asia and overseas. Botaniex's goal is to become a major player in the multi-billion dollar global herbal products industry.
For more information please contact CEO Melson Liao at melsonliao@botaniex.com or visit the Corporate website at www.botaniex.com.
Forward-Looking Statements
Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company's stock is not currently registered with the Securities and Exchange Commission.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
